Barbara Ryan sold $22k of INKT
director at MiNK Therapeutics, Inc.. 1,500 shares at an average of $14.70, traded Mar 9, 2026, filed Mar 11, 2026.
Score components
- +15RoleDirector
- 0Trade size$22k at market
- 0Share of holdings soldSold 6.8% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.3%, 3m +9.0%, 6m +6.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-102581, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | SOpen-market sale Common Stock | -200 | $10.17 | $2,035 | 21,706 | Mar 11, 2026 |
| Mar 10, 2026 | SOpen-market sale Common Stock | -300 | $15.28 | $4,585 | 21,406 | Mar 11, 2026 |
| Mar 10, 2026 | SOpen-market sale Common Stock | -500 | $15.57 | $7,783 | 20,906 | Mar 11, 2026 |
| Mar 10, 2026 | SOpen-market sale Common Stock | -500 | $15.30 | $7,650 | 20,406 | Mar 11, 2026 |
Related signals
Other insiders at MiNK Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | INKTsell MiNK Therapeutics, Inc. | Barbara Ryan director | $19k 1,500 shares | -6% | |
| 15Weak | INKTsell MiNK Therapeutics, Inc. | Barbara Ryan director | $5,426 500 shares | -2% | |
| 15Weak | INKTbuy MiNK Therapeutics, Inc. | Agenus Inc owner | $25k 22,975 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.